ReviewInfectious agents and cancer2026
Silencing HPV: the rise of RNA therapeutics in cervical cancer.
Review in Infectious agents and cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The interplay between HPV, vaginal microbiota and host immunity in cervical carcinogenesis.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the availability of preventative HPV vaccinations, cervical cancer remains a worldwide health concern. It is mostly caused by persistent infection with high-risk human papillomaviruses. Therapeutic techniques targeting the viral oncogenes E6 and E7, which are constitutively expressed in HPV-positive cervical cancers and inactivate the important tumor suppressors, p53 and Rb, offer intriguing molecular treatment options. RNA-based techniques, such as tiny interfering RNA, short hairpin RNA, antisense oligonucleotides, and mRNA-based vaccines for the selective silencing of E6/E7 genes, have emerged as leaders in targeted therapeutics. Preclinical studies have shown that RNA-mediated suppression of E6/E7 can restore p53 and Rb activity, causing apoptosis or senescence in cervical cancer cells and inhibiting tumor growth in animal models. Similarly, mRNA vaccination platforms encoding E6/E7 have been found to potently induce HPV T-cell responses and full tumor regression in animal models. RNA-based therapeutics in patients are now being evaluated in early-stage clinical studies, including novel mRNA vaccines for HPV-positive malignancies in combination with immunotherapies. While no RNA-based treatment for cervical cancer has yet achieved regulatory approval, this review summarizes the significant progress in this field that has been effective in therapies for cervical cancer using new strategies, such as advanced delivery systems, combinatorial treatments, and genome editing strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.